Sher Fertility Solutions New York – FDA 483, Apr 1, 2022
An FDA inspection of Sher Fertility Solutions New York identified two significant observations related to reproductive human tissue. The firm failed to collect donor specimens for communicable disease testing, specifically West Nile Virus, at appropriate times for anonymous oocyte donors. Additionally, the firm did not establish and maintain adequate procedures for testing HCT/P donors, with their SOP lacking sufficient detail for donor eligibility, West Nile Virus testing, and ZIKV risk identification.
ID · 4fc26623-af9a-4c60-bf74-0407d80493c6
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.